Naz Rahman
Stock Analyst at Maxim Group
(0.15)
# 4,150
Out of 4,829 analysts
38
Total ratings
12.5%
Success rate
-44.01%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.24 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $8.99 | +89.10% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $9 → $5 | $0.98 | +407.72% | 2 | Mar 20, 2025 | |
| SCPH scPharmaceuticals | Maintains: Buy | $20 → $12 | $2.44 | +391.80% | 3 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $27.55 | +154.08% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.04 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $4.01 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $0.73 | +1,002.69% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $1.86 | - | 2 | Oct 24, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $3 | $0.61 | +391.80% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $6.23 | +2,147.19% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $424.99 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.12 | +83,163.95% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.24 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.26 | +296.83% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.09 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.59 | +131.66% | 1 | Feb 25, 2022 |
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.24
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $8.99
Upside: +89.10%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $9 → $5
Current: $0.98
Upside: +407.72%
scPharmaceuticals
Mar 20, 2025
Maintains: Buy
Price Target: $20 → $12
Current: $2.44
Upside: +391.80%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $27.55
Upside: +154.08%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.04
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $4.01
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $0.73
Upside: +1,002.69%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.86
Upside: -
Assertio Holdings
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.61
Upside: +391.80%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $6.23
Upside: +2,147.19%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $424.99
Upside: -
Dec 8, 2023
Initiates: Buy
Price Target: $100
Current: $0.12
Upside: +83,163.95%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.24
Upside: -
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $1.26
Upside: +296.83%
May 9, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.09
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.59
Upside: +131.66%